为解决缺乏芽殖酵母 SUMO（Smt3）特异性研究工具及相关修饰机制不明的问题，德国分子生物学研究所的研究人员开展了针对 Smt3 的 DARPin 亲和探针研究，发现了 DNA 损伤诱导的、不依赖单链 DNA 的染色质 SUMO 化修饰，为相关研究提供了新工具和见解。 在细胞的生命 ...

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or ...

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on ...

Participation in fireside chats at TD Cowen and Leerink healthcare conferences Call on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., ...

Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin ...

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearance Strategic partnership with Orano Med on Radio-DARPins now expanded to ten programs MP0533 ...